Ovid Therapeutics Inc Financials

OVID

Source SEC Filings (10-K/10-Q) Updated Sep 30, 2025 Currency USD FYE December

Financial Health Signals

Financial Profile 60/100

Based on FY2024 annual data. Scores normalized against common benchmarks. How we calculate these scores

Profitability

Ovid Therapeutics Inc has an operating margin of -10933.8%, meaning the company retains $-10934 of operating profit per $100 of revenue. This below-average margin results in a low score of 0/100, suggesting thin profitability after operating expenses. This is up from -15122.7% the prior year.

Growth

100

Ovid Therapeutics Inc's revenue surged 44.4% year-over-year to $566K, reflecting rapid business expansion. This strong growth earns a score of 100/100.

Leverage

Ovid Therapeutics Inc carries a low D/E ratio of 0.35, meaning only $0.35 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 98/100, indicating a strong balance sheet with room for future borrowing.

Liquidity

100

With a current ratio of 5.32, Ovid Therapeutics Inc holds $5.32 in current assets for every $1 of short-term obligations. This comfortable liquidity earns a score of 100/100.

Cash Flow

While Ovid Therapeutics Inc generated -$56.0M in operating cash flow, capex of $71K consumed most of it, leaving -$56.0M in free cash flow. This results in a low score of 0/100, reflecting heavy capital investment rather than weak cash generation.

Piotroski F-Score Weak

2/9

Ovid Therapeutics Inc passes 2 of 9 financial strength tests. 1 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), both operating efficiency signals pass.

Earnings Quality Low Quality

2.12x

For every $1 of reported earnings, Ovid Therapeutics Inc generates $2.12 in operating cash flow (-$56.0M OCF vs -$26.4M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.

This page shows Ovid Therapeutics Inc (OVID) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 10 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Export CSV

Key Financial Metrics

Revenue

$566K

YoY+44.4%

Ovid Therapeutics Inc generated $566K in revenue in fiscal year 2024. This represents an increase of 44.4% from the prior year.

EBITDA

-$61.3M

YoY-4.4%

Ovid Therapeutics Inc's EBITDA was -$61.3M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 4.4% from the prior year.

Free Cash Flow

-$56.0M

YoY-22.3%

Ovid Therapeutics Inc generated -$56.0M in free cash flow in fiscal year 2024, representing cash available after capex. This represents a decrease of 22.3% from the prior year.

Net Income

-$26.4M

YoY+49.5%

Ovid Therapeutics Inc reported -$26.4M in net income in fiscal year 2024. This represents an increase of 49.5% from the prior year.

EPS (Diluted)

N/A

Cash & Debt

$26.3M

YoY-2.7%

5Y CAGR-8.9%

Ovid Therapeutics Inc held $26.3M in cash against $0 in long-term debt as of fiscal year 2024.

Dividends Per Share

N/A

Shares Outstanding

71M

YoY+0.4%

5Y CAGR+5.4%

Ovid Therapeutics Inc had 71M shares outstanding in fiscal year 2024. This represents an increase of 0.4% from the prior year.

Gross Margin

N/A

Operating Margin

-10933.8%

YoY+4188.9pp

Ovid Therapeutics Inc's operating margin was -10933.8% in fiscal year 2024, reflecting core business profitability. This is up 4188.9 percentage points from the prior year.

Net Margin

-4670.1%

YoY+8681.6pp

Ovid Therapeutics Inc's net profit margin was -4670.1% in fiscal year 2024, showing the share of revenue converted to profit. This is up 8681.6 percentage points from the prior year.

Return on Equity

N/A

R&D Spending

$36.8M

YoY+28.6%

5Y CAGR-2.7%

Ovid Therapeutics Inc invested $36.8M in research and development in fiscal year 2024. This represents an increase of 28.6% from the prior year.

Share Buybacks

N/A

Capital Expenditures

$71K

YoY+77.5%

5Y CAGR+4.4%

Ovid Therapeutics Inc invested $71K in capex in fiscal year 2024, funding long-term assets and infrastructure. This represents an increase of 77.5% from the prior year.

OVID Income Statement

Metric	FY24	FY23	FY22	FY21	FY20	FY19
Revenue	$566K+44.4%	$392K-73.9%	$1.5M-99.3%	$208.4M+1551.6%	$12.6M	N/A
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	$36.8M+28.6%	$28.6M+16.1%	$24.6M-47.6%	$46.9M-26.0%	$63.4M+50.4%	$42.2M
SG&A Expenses	$25.7M-17.4%	$31.1M-4.2%	$32.4M-12.9%	$37.2M+21.6%	$30.6M+59.1%	$19.3M
Operating Income	-$61.9M-4.4%	-$59.3M-6.7%	-$55.5M-144.7%	$124.2M+252.5%	-$81.4M-32.6%	-$61.4M
Interest Expense	N/A	N/A	N/A	N/A	N/A	N/A
Income Tax	$0	$0	$0-100.0%	$1.3M	$0	$0
Net Income	-$26.4M+49.5%	-$52.3M+3.4%	-$54.2M-144.1%	$122.8M+251.6%	-$81.0M-34.0%	-$60.5M
EPS (Diluted)	N/A	$-0.74+3.9%	$-0.77-143.8%	$1.76+226.6%	$-1.39	N/A

Metric	Q3'25	Q2'25	Q1'25	Q3'24	Q2'24	Q1'24	Q4'23	Q3'23
Revenue	$132K-97.9%	$6.3M+4724.6%	$130K+71.1%	$76K-55.0%	$169K+14.2%	$148K+4.2%	$142K+30.3%	$109K
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	$5.9M-9.2%	$6.5M-2.9%	$6.7M+12.2%	$5.9M-52.8%	$12.6M+21.0%	$10.4M-2.3%	$10.6M+99.5%	$5.3M
SG&A Expenses	$6.8M+39.0%	$4.9M-19.0%	$6.0M+23.7%	$4.9M-39.9%	$8.1M+13.1%	$7.2M-6.8%	$7.7M+13.0%	$6.8M
Operating Income	-$12.5M-146.9%	-$5.1M+59.6%	-$12.6M-17.0%	-$10.7M+47.7%	-$20.5M-17.8%	-$17.4M+4.2%	-$18.2M-51.2%	-$12.0M
Interest Expense	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Income Tax	$0	$0	$0	$0	$0	$0	$0	$0
Net Income	-$12.2M-159.6%	-$4.7M+54.2%	-$10.2M-10.6%	-$9.3M-208.6%	$8.5M+172.9%	-$11.7M+23.7%	-$15.3M-36.2%	-$11.3M
EPS (Diluted)	N/A	N/A	N/A	$-0.20-266.7%	$0.12+170.6%	$-0.17+19.0%	$-0.21-31.2%	$-0.16

OVID Balance Sheet

Metric	FY24	FY23	FY22	FY21	FY20	FY19
Total Assets	$92.2M-36.0%	$144.0M-7.2%	$155.3M-20.2%	$194.5M+156.2%	$75.9M-6.1%	$80.8M
Current Assets	$55.9M-49.0%	$109.6M-16.6%	$131.4M-31.0%	$190.5M+154.5%	$74.8M-6.2%	$79.8M
Cash & Equivalents	$26.3M-2.7%	$27.0M-39.7%	$44.9M-76.1%	$187.8M+160.7%	$72.0M+71.9%	$41.9M
Inventory	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$23.9M-57.4%	$56.2M+144.6%	$23.0M+55.4%	$14.8M-54.2%	$32.3M+198.5%	$10.8M
Current Liabilities	$10.5M-8.3%	$11.5M+64.1%	$7.0M-52.8%	$14.8M-32.9%	$22.1M+109.5%	$10.5M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$68.2M-22.3%	$87.8M-33.6%	$132.3M-26.4%	$179.7M+312.0%	$43.6M-37.7%	$70.0M
Retained Earnings	-$304.3M-9.5%	-$277.9M-23.2%	-$225.5M-31.6%	-$171.4M+41.8%	-$294.2M-38.0%	-$213.2M

Metric	Q3'25	Q2'25	Q1'25	Q3'24	Q2'24	Q1'24	Q4'23	Q3'23
Total Assets	$63.8M-17.5%	$77.4M-5.2%	$81.7M-11.4%	$92.2M-22.0%	$118.1M-10.3%	$131.6M-8.6%	$144.0M+15.2%	$125.0M
Current Assets	$28.8M-31.5%	$42.1M-8.3%	$45.9M-17.9%	$55.9M-30.8%	$80.9M-13.2%	$93.2M-15.0%	$109.6M+19.5%	$91.7M
Cash & Equivalents	$20.6M-27.5%	$28.4M+34.4%	$21.1M-19.6%	$26.3M-11.4%	$29.7M-3.5%	$30.8M+13.8%	$27.0M-52.9%	$57.4M
Inventory	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$19.1M-11.5%	$21.6M-3.3%	$22.4M-6.5%	$23.9M-18.0%	$29.2M-45.3%	$53.3M-5.2%	$56.2M+136.9%	$23.7M
Current Liabilities	$6.8M-23.8%	$8.9M-4.1%	$9.3M-11.5%	$10.5M-25.5%	$14.1M+58.6%	$8.9M-22.4%	$11.5M+32.4%	$8.7M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$44.7M-19.9%	$55.8M-5.9%	$59.3M-13.1%	$68.2M-23.3%	$88.9M+13.6%	$78.3M-10.8%	$87.8M-13.3%	$101.3M
Retained Earnings	-$331.4M-3.8%	-$319.2M-1.5%	-$314.5M-3.4%	-$304.3M-8.3%	-$281.0M+2.9%	-$289.6M-4.2%	-$277.9M-5.8%	-$262.5M

OVID Cash Flow Statement

Metric	FY24	FY23	FY22	FY21	FY20	FY19
Operating Cash Flow	-$56.0M-22.2%	-$45.8M+17.1%	-$55.2M-146.6%	$118.6M+329.9%	-$51.6M-1.0%	-$51.1M
Capital Expenditures	$71K+77.5%	$40K-96.7%	$1.2M+565.4%	$184K+44.6%	$127K+122.6%	$57K
Free Cash Flow	-$56.0M-22.3%	-$45.8M+18.8%	-$56.5M-147.7%	$118.4M+329.0%	-$51.7M-1.1%	-$51.1M
Investing Cash Flow	$54.6M+2215.2%	-$2.6M+97.1%	-$87.9M-4725.0%	-$1.8M-105.3%	$34.6M+215.3%	-$30.0M
Financing Cash Flow	$622K-98.0%	$30.5M+16802.1%	$181K-80.0%	$904K-98.1%	$47.1M-45.6%	$86.5M
Dividends Paid	$0	$0	$0	$0	$0	$0
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q3'25	Q2'25	Q1'25	Q3'24	Q2'24	Q1'24	Q4'23	Q3'23
Operating Cash Flow	-$12.9M-169.6%	-$4.8M+53.6%	-$10.3M-2.7%	-$10.0M+29.8%	-$14.3M+14.6%	-$16.7M-40.1%	-$11.9M-18.5%	-$10.1M
Capital Expenditures	$0	$0	$0-100.0%	$22K-35.3%	$34K+78.9%	$19K+46.2%	$13K+116.7%	$6K
Free Cash Flow	-$12.9M-169.6%	-$4.8M+53.6%	-$10.3M-2.5%	-$10.0M+29.8%	-$14.3M+14.5%	-$16.7M-40.1%	-$11.9M-18.6%	-$10.1M
Investing Cash Flow	$5.1M-58.1%	$12.1M+136.2%	$5.1M-76.0%	$21.3M+66.1%	$12.8M-36.5%	$20.2M+141.6%	-$48.5M-1012.8%	-$4.4M
Financing Cash Flow	$15K	$0-100.0%	$13K	$0-100.0%	$356K+56.1%	$228K-99.2%	$30.0M+13307.6%	$224K
Dividends Paid	$0	$0	$0	$0	$0	$0	$0	$0
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

OVID Financial Ratios

Metric	FY24	FY23	FY22	FY21	FY20	FY19
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	-10933.8%+4188.9pp	-15122.7%-11426.3pp	-3696.4%-3756.0pp	59.6%+705.0pp	-645.4%	N/A
Net Margin	-4670.1%+8681.6pp	-13351.8%-9747.1pp	-3604.7%-3663.6pp	59.0%+701.2pp	-642.3%	N/A
Return on Equity	N/A	N/A	N/A	68.3%	N/A	N/A
Return on Assets	-28.7%+7.7pp	-36.3%-1.5pp	-34.9%-98.0pp	63.1%+169.9pp	-106.7%-31.9pp	-74.8%
Current Ratio	5.32-4.2	9.55-9.2	18.79+5.9	12.87+9.5	3.39-4.2	7.58
Debt-to-Equity	0.35-0.3	0.64+0.5	0.17+0.1	0.08-0.7	0.74+0.6	0.15
FCF Margin	-9898.8%+1790.3pp	-11689.0%-7932.5pp	-3756.6%-3813.4pp	56.8%+466.7pp	-409.8%	N/A

Metric	Q3'25	Q2'25	Q1'25	Q3'24	Q2'24	Q1'24	Q4'23	Q3'23
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	-9487.1%-9406.2pp	-80.9%+9573.0pp	-9653.9%+4458.0pp	-14111.8%-1971.6pp	-12140.2%-372.0pp	-11768.2%+1040.2pp	-12808.4%-1772.7pp	-11035.8%
Net Margin	-9210.6%-9135.9pp	-74.7%+7798.4pp	-7873.1%+4303.2pp	-12176.3%-17218.3pp	5042.0%+12943.4pp	-7901.3%+2888.8pp	-10790.1%-466.3pp	-10323.9%
Return on Equity	N/A	N/A	N/A	N/A	9.6%	N/A	N/A	N/A
Return on Assets	-19.0%-13.0pp	-6.0%+6.5pp	-12.5%-2.5pp	-10.0%-17.3pp	7.2%+16.1pp	-8.9%+1.7pp	-10.6%-1.6pp	-9.0%
Current Ratio	4.24-0.5	4.72-0.2	4.93-0.4	5.32-0.4	5.73-4.7	10.46+0.9	9.55-1.0	10.59
Debt-to-Equity	0.43+0.0	0.39+0.0	0.38+0.0	0.35+0.0	0.33-0.4	0.68+0.0	0.64+0.4	0.23
FCF Margin	-9751.5%-9675.4pp	-76.1%+7831.6pp	-7907.7%+5289.7pp	-13197.4%-4742.3pp	-8455.0%+2832.1pp	-11287.2%-2890.0pp	-8397.2%+830.3pp	-9227.5%

Similar Companies

Xbiotech XBIT

$74.7M

Atara Biotherape ATRA

$32.1M

Quince QNCX

$11.1M

Entera Bio Ltd ENTX

$68.8M

Opus Genetics IRD

$251.0M

Frequently Asked Questions

What is Ovid Therapeutics Inc's annual revenue?

Ovid Therapeutics Inc (OVID) reported $566K in total revenue for fiscal year 2024. This represents a 44.4% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is Ovid Therapeutics Inc's revenue growing?

Ovid Therapeutics Inc (OVID) revenue grew by 44.4% year-over-year, from $392K to $566K in fiscal year 2024.

Is Ovid Therapeutics Inc profitable?

No, Ovid Therapeutics Inc (OVID) reported a net income of -$26.4M in fiscal year 2024, with a net profit margin of -4670.1%.

What is Ovid Therapeutics Inc's EBITDA?

Ovid Therapeutics Inc (OVID) had EBITDA of -$61.3M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization.

What is Ovid Therapeutics Inc's operating margin?

Ovid Therapeutics Inc (OVID) had an operating margin of -10933.8% in fiscal year 2024, reflecting the profitability of core business operations before interest and taxes.

What is Ovid Therapeutics Inc's net profit margin?

Ovid Therapeutics Inc (OVID) had a net profit margin of -4670.1% in fiscal year 2024, representing the share of revenue converted into profit after all expenses.

What is Ovid Therapeutics Inc's free cash flow?

Ovid Therapeutics Inc (OVID) generated -$56.0M in free cash flow during fiscal year 2024. This represents a -22.3% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is Ovid Therapeutics Inc's operating cash flow?

Ovid Therapeutics Inc (OVID) generated -$56.0M in operating cash flow during fiscal year 2024, representing cash generated from core business activities.

What are Ovid Therapeutics Inc's total assets?

Ovid Therapeutics Inc (OVID) had $92.2M in total assets as of fiscal year 2024, including both current and long-term assets.

What are Ovid Therapeutics Inc's capital expenditures?

Ovid Therapeutics Inc (OVID) invested $71K in capital expenditures during fiscal year 2024, funding long-term assets and infrastructure.

How much does Ovid Therapeutics Inc spend on research and development?

Ovid Therapeutics Inc (OVID) invested $36.8M in research and development during fiscal year 2024.

How many shares does Ovid Therapeutics Inc have outstanding?

Ovid Therapeutics Inc (OVID) had 71M shares outstanding as of fiscal year 2024.

What is Ovid Therapeutics Inc's current ratio?

Ovid Therapeutics Inc (OVID) had a current ratio of 5.32 as of fiscal year 2024, which is generally considered healthy.

What is Ovid Therapeutics Inc's debt-to-equity ratio?

Ovid Therapeutics Inc (OVID) had a debt-to-equity ratio of 0.35 as of fiscal year 2024, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Ovid Therapeutics Inc's return on assets (ROA)?

Ovid Therapeutics Inc (OVID) had a return on assets of -28.7% for fiscal year 2024, measuring how efficiently the company uses its assets to generate profit.

What is Ovid Therapeutics Inc's cash runway?

Based on fiscal year 2024 data, Ovid Therapeutics Inc (OVID) had $26.3M in cash against an annual operating cash burn of $56.0M. This gives an estimated cash runway of approximately 6 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.

What is Ovid Therapeutics Inc's Piotroski F-Score?

Ovid Therapeutics Inc (OVID) has a Piotroski F-Score of 2 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Ovid Therapeutics Inc's earnings high quality?

Ovid Therapeutics Inc (OVID) has an earnings quality ratio of 2.12x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

How financially healthy is Ovid Therapeutics Inc?

Ovid Therapeutics Inc (OVID) scores 60 out of 100 on our Financial Profile, indicating moderate overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.